← Back to Search

Other

ADI PEG20 for Uveal Melanoma

Q: Has the FDA given its stamp of approval to ADI PEG20?

There is only minimal evidence that ADI PEG20 offers a safe and effective treatment, so it received the lowest rating of 1 on our scale.

Q: How many individuals are involved in this experiment?

As of now, this clinical trial is not seeking out new participants. This medical study was first published on April 16th 2019 and last updated January 10th 2022. For those looking for alternative trials connected to uveal neoplasms, 755 are currently recruiting patients while there are 764 studies actively enrolling individuals that would benefit from ADI PEG20 therapy.

Q: Could patients join this investigation at the present time?

Unfortunately, this clinical study is not actively recruiting for participants as per the latest update on clinicaltrials.gov dated January 10th 2022. Despite that, there are numerous other trials currently in progress and seeking candidates - 1,519 to be exact.

Q: Are there any further investigations into the effects of ADI PEG20?

Presently, there are 764 clinical trials being conducted for ADI PEG20; 86 of those studies have reached Phase 3. The majority of tests are being carried out in Pittsburgh, <a href="https://www.withpower.com/clinical-trials/pennsylvania">Pennsylvania</a> while a total of 42760 sites across the world host these tests.

Q: What maladies does ADI PEG20 typically alleviate?

ADI PEG20 is commonly used for anti-angiogenic therapy, but it can also be employed to manage a variety of malignancies like <a href="https://www.withpower.com/clinical-trials/squamous-cell-carcinoma">squamous cell carcinoma</a> and melanomas that have become resistant to traditional treatments.

Phase 1

Waitlist Available

Led By Alexander Shoushtari, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have an Easter Cooperative Oncology Group (ECOG) Performance Statue (PS) of 0-1.

Total bilirubin </= 1.5x upper limit of normal (ULN); patients with Gilbert's Syndrome must have bilirubin </= 3x ULN

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial is testing a new combination treatment for advanced uveal melanoma. The goal is to see if it is safe and effective.

Eligible Conditions

Uveal Melanoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety as assessed by CTCAE version 5.0

Secondary outcome measures

Objective Response Rate by RECIST 1.1

Trial Design

1Treatment groups

Experimental Treatment

Group I: Advanced Uveal MelanomaExperimental Treatment3 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ipilimumab

2014

Completed Phase 3

~2670

ADI PEG20

2019

Completed Phase 1

~10

Nivolumab

2014

Completed Phase 3

~4750

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,932 Previous Clinical Trials

585,525 Total Patients Enrolled

Alexander Shoushtari, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

3 Previous Clinical Trials

40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given its stamp of approval to ADI PEG20?

"There is only minimal evidence that ADI PEG20 offers a safe and effective treatment, so it received the lowest rating of 1 on our scale."

Answered by AI

How many individuals are involved in this experiment?

"As of now, this clinical trial is not seeking out new participants. This medical study was first published on April 16th 2019 and last updated January 10th 2022. For those looking for alternative trials connected to uveal neoplasms, 755 are currently recruiting patients while there are 764 studies actively enrolling individuals that would benefit from ADI PEG20 therapy."

Answered by AI

Could patients join this investigation at the present time?

"Unfortunately, this clinical study is not actively recruiting for participants as per the latest update on clinicaltrials.gov dated January 10th 2022. Despite that, there are numerous other trials currently in progress and seeking candidates - 1,519 to be exact."

Answered by AI

Are there any further investigations into the effects of ADI PEG20?

"Presently, there are 764 clinical trials being conducted for ADI PEG20; 86 of those studies have reached Phase 3. The majority of tests are being carried out in Pittsburgh, Pennsylvania while a total of 42760 sites across the world host these tests."

Answered by AI

What maladies does ADI PEG20 typically alleviate?

"ADI PEG20 is commonly used for anti-angiogenic therapy, but it can also be employed to manage a variety of malignancies like squamous cell carcinoma and melanomas that have become resistant to traditional treatments."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

2019. "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03922880.